DiaMedica Announces Influenza Program and Enters Into an Evaluation Agreement With the U.S. National Institute of Allergy and In
January 26 2011 - 9:06AM
Marketwired
DiaMedica (TSX VENTURE: DMA) is pleased to announce preliminary
results of its influenza program with its monoclonal antibody
program (mAb) and the entering into an evaluation agreement with
the National Institute of Allergy and Infectious Diseases (NIAID),
a component of the U.S. National Institute of Health (NIH), to
further test for the treatment of influenza infection in animal
models.
DiaMedica's mAb was able to dose dependently prevent influenza
replication in an in vitro host cell model.
"The Company believes that the mechanism of the mAb inhibits a
key host protein, GSK3B, that can prevent influenza entry and/or
replication in host cells. Thus the mAb has the potential to
protect against all strains of influenza viruses because the
antibody is targeting the host cells and not the influenza virus
itself," stated Dr. Mark Williams, VP Research.
The upcoming animal studies are being conducted under the
antiviral screening program offered by the U.S. Division of
Microbiology and Infectious Diseases (DMID) of the NIAID, a part of
the NIH. The studies conducted by Utah State University are focused
on providing key efficacy data towards supporting the filing of an
Investigational New Drug (IND) application to treat influenza for
the novel mAb.
About NIAID
National Institute of Allergy and Infectious Diseases (NIAID)
conducts and supports basic and applied research to better
understand, treat, and ultimately prevent infectious, immunologic,
and allergic diseases. For more than 60 years, NIAID research has
led to new therapies, vaccines, diagnostic tests, and other
technologies that have improved the health of millions of people in
the United States and around the world.
NIAID support for influenza research over the past several years
has greatly improved our preparedness for and ability to respond to
a pandemic influenza. Scientists in NIAID laboratories and NIAID
contractors worldwide began studying diverse influenza viruses well
before the outbreak of the 2009 HINI influenza, and are continuing
to prepare for seasonal as well as pandemic influenza
outbreaks.
About DiaMedica
DiaMedica is a biopharmaceutical company developing novel
treatments for diabetes and other disorders. Two of DiaMedica's
products, DM-71 and DM-99 have demonstrated phase II human efficacy
in lowering blood glucose levels in people diagnosed with type 2
diabetes.
DiaMedica's lead product DM-199 is an improved, recombinant form
of the naturally-occurring DM-99 to treat diabetes while also
demonstrating activity in neurological and autoimmune disorders.
The Company has shown that DM-99, the naturally-occurring form of
DM-199, confers neural protection (protects brain cells) and
triggers neural stem cell proliferation (creates brain cells) for
the treatment of numerous neurological disorders including
Alzheimer's disease.
For further information please visit www.diamedica.com.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable
Canadian provincial securities legislation (collectively, the
"forward-looking statements"). These forward-looking statements
relate to, among other things, DiaMedica's objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, and can, in some cases, be identified by the use of words
such as "believe," "anticipate," "expect," "intend," "plan,"
"will," "may" and other similar expressions. In addition, any
statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements. Specifically, this press release
contains forward-looking statements regarding matters such as, but
not limited to, the anticipated use of proceeds from the Offering,
management's assessment of DiaMedica's future plans, information
with respect to the advancement of DiaMedica's research and
development programs, and DiaMedica's other estimates and
expectations. These statements reflect management's current beliefs
and are based on information currently available to management.
Certain material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
uncertainties and risks related to our research and development
programs, the availability of additional financing, risks and
uncertainties relating to the anticipated use of proceeds, changes
in debt and equity markets, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, the cost and supply of raw materials, management
of growth, effects of insurers' willingness to pay for products,
risks related to regulatory matters and risks related to
intellectual property matters. Additional information about these
factors and about the material factors or assumptions underlying
such forward-looking statements may be found in the body of this
news release, as well as under the heading "Risk Factors" contained
in DiaMedica's 2009 annual information form.
DiaMedica cautions that the foregoing list of important factors
that may affect future results is not exhaustive. When relying on
DiaMedica's forward-looking statements to make decisions with
respect to DiaMedica, investors and others should carefully
consider the foregoing factors and other uncertainties and
potential events. Such forward-looking statements are based on a
number of estimates and assumptions, which may prove to be
incorrect, including, but not limited to, assumptions regarding the
availability of additional financing for research and development
companies, and general business and economic conditions. These
risks and uncertainties should be considered carefully and
investors and others should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, DiaMedica cannot provide
assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to
update or revise any forward-looking statement. Additional risk
factors, factors which could cause actual results to differ
materially from expectations, and assumptions relating specifically
to our acquisition of Sanomune may be found in our press releases
dated February 18, 2010 and April 20, 2010.
Contacts: DiaMedica Inc. Rick Pauls Chairman & CEO
204.477.7590 204.453.3745 (FAX) rpauls@diamedica.com
www.diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024